AMNEAL PHARMACEUTICALS, INC. Current Federal Tax Expense (Benefit)
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Current Federal Tax Expense (Benefit) of -$1.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2025 was -$1.88M, a 156.54% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2024 was $3.33M, a 1201.56% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2023 was $256.00K.
- AMNEAL PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2022 was -$1.07M, a 181.85% decline from fiscal 2021.
| Period end | Current Federal Tax Expense (Benefit) | Current Federal Tax Expense (Benefit) 12 month | Current Federal Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$1.88M 10-K · filed 2026-02-27 | ||
| 2024-12-31 | $3.33M 10-K · filed 2026-02-27 | $8.31M 10-K · filed 2025-02-28 | |
| 2023-12-31 | $256.00K 10-K · filed 2026-02-27 | $2.47M 10-K · filed 2024-03-14 | |
| 2022-12-31 | -$1.07M 10-K · filed 2025-02-28 | ||
| 2021-12-31 | $1.31M 10-K · filed 2024-03-14 | ||
| 2020-12-31 | -$113.75M 10-K · filed 2023-03-03 | ||
| 2020-03-27 | $110.00M 10-Q · filed 2020-05-11 | ||
| 2019-12-31 | -$2.76M 10-K · filed 2022-03-01 | ||
| 2018-12-31 | $2.30M 10-K · filed 2021-03-01 | ||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |